ABSTRACT:
An innovative analytical approach for the thorough impurity profiling of the key antiretroviral medication Bictegravir was developed and validated in this work. The approach was very precise in its ability to isolate and resolve Bictegravir from its constituent contaminants. Thorough evaluations of peak purity verified that there was no co-elution, guaranteeing that each peak reflected a distinct component. Extensive evaluation of precision at the limit of quantitation (LOQ) demonstrated that the approach could consistently and reliably quantify Bictegravir and its contaminants. Specificity, accuracy, precision, and resilience were some of the critical performance metrics that were thoroughly tested during the validation process. The findings confirm the method's accuracy and dependability, guaranteeing the drug substance's safety and purity. With this proven analytical approach, pharmaceutical quality control will be a breeze. It will help with exact monitoring of Bictegravir's concentration and purity in different medication formulations, which means the medicine will be used safely and effectively.
Cite this article:
Upama Surendra Singh, Navin Sainy. Analytical Method Development and Validation for Impurity Profiling of Bictegravir as an Antiretroviral Drug. Research Journal Pharmacy and Technology. 2026;19(3):1301-7. doi: 10.52711/0974-360X.2026.00186
Cite(Electronic):
Upama Surendra Singh, Navin Sainy. Analytical Method Development and Validation for Impurity Profiling of Bictegravir as an Antiretroviral Drug. Research Journal Pharmacy and Technology. 2026;19(3):1301-7. doi: 10.52711/0974-360X.2026.00186 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-47
REFERENCES:
1. Jain P, et al. Comprehensive review on different analytical techniques for HIV 1-integrase inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir. Critical Reviews in Analytical Chemistry. 2024; Feb 17; 54(2): 401-15.
2. Kumar SJ, et al. Determination and quantification of related substances and degradation products in bictegravir by full factorial design evaluated HPLC and mass spectrometry. Analytical Methods. 2023; 15(10): 1274-85.
3. Karmakar R, et al. A critical review of analytical and bio-analytical methods for the estimation of anti-HIV drug bictegravir.
4. Lamichhane S, et al. Overview of forced degradation analysis for FDA-approved antiretroviral agents: A review. Journal of Young Pharmacists. 2022; Jul 1; 14(3).
5. Kumari KP, Sankar DG. Stability-indicating UPLC method for simultaneous estimation of emtricitabine, bictegravir and tenofovir alafenamide. Indian Drugs. 2020; Jan 1; 57(1).
6. Konam K, Reddy KS. Stability-indicating RP-UPLC method for simultaneous estimation of emtricitabine, tenofovir and bictegravir in bulk and pharmaceutical dosage form. International Journal of Life Sciences and Pharmaceutical Research. 2020; 10(5): P90-101.
7. Mishra RK, et al. A review of analytical techniques for determination of anti-HIV drugs. International Journal of Applied Pharmaceutics. 2020; Nov 7; 12(6): 41-50.
8. Saminathan J, Vetrichelvan T. Development and validation of HPTLC method for simultaneous estimation of emtricitabine, rilpivirine and tenofovir disoproxil fumarate in combined dosage form. Bangladesh Pharmaceutical Journal. 2016; 19(1): 114-21.
9. Jabeen N, Haque MA. A review on bioanalytical method development and validation for estimation of drugs by using hyphenated techniques and its applications on routine analysis. Archives of Current Research International. 2023; Mar 1; 23(2): 18-35.
10. Patel K, Shah U, Joshi H, Patel JK, Patel TB. Development, validation and forced degradation study of emtricitabine and tenofovir alafenamide in its pharmaceutical dosage form using RP-HPLC. Journal of Pharmaceutical Research International. 2021; 33(43A): 37-46. doi: 10.9734/jpri/2021/v33i43A32462.
11. Holm R, Elder DP. Analytical advances in pharmaceutical impurity profiling. European Journal of Pharmaceutical Sciences. 2016; May 25; 87: 118-35.
12. Venkatesan P, Valliappan K. Impurity profiling: theory and practice. Journal of Pharmaceutical Sciences and Research. 2014; Jul 1; 6(7): 254.
13. Mahajan PS, Burke Jr TR. Synthetic approaches to a key pyridone-carboxylic acid precursor common to the HIV-1 integrase strand transfer inhibitors dolutegravir, bictegravir, and cabotegravir. Organic Process Research and Development. 2023; Apr 20; 27(5): 847-53.
14. Menendez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends in Pharmacological Sciences. 2022; Jan 1; 43(1): 16-29.
15. Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Current Opinion in HIV and AIDS. 2018; Jul 1; 13(4): 326-33.
16. Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018; Nov; 78(17): 1817-28.
17. Thakare BN, Mittal A, Charde SM. Validated stability-indicating assay UHPLC method for simultaneous estimation of doravirine, lamivudine and tenofovir disoproxil fumarate in pure material and pharmaceutical matrix.
18. Nannou C, Ofrydopoulou A, Evgenidou E, Heath D, Heath E, Lambropoulou D. Analytical strategies for the determination of antiviral drugs in the aquatic environment. Trends in Environmental Analytical Chemistry. 2019; Oct 1; 24: e00071.
19. Ahmed F, Eticha T, Hymete A, Ashenef A. Principles and applications of ultra-high-performance liquid chromatography. In: High-Performance Liquid Chromatography - Recent Advances and Applications. 2023; Mar 28. IntechOpen.
20. Attaluri T, Ganapaty SE, Varanasi SN. Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of bictegravir, emtricitabine, and tenofovir alafenamide fumarate. Turkish Journal of Pharmaceutical Sciences. 2021; Aug; 18(4): 410.
21. Mohammed Rizwan U. Development and validation of stability-indicating RP-HPLC method for the simultaneous estimation of cabotegravir and rilpivirine in bulk and tablet dosage form (Doctoral dissertation, JKK Nattraja College of Pharmacy, Kumarapalayam).